Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome.

Adolescent Attention Deficit Disorder with Hyperactivity / etiology Child DiGeorge Syndrome / complications Disease Progression Female Humans Longitudinal Studies Male Psychotic Disorders / etiology
22q11.2DS ADHD Inattention Psychotic symptoms

Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
02 2019
Historique:
received: 18 05 2018
revised: 16 07 2018
accepted: 31 07 2018
pubmed: 11 8 2018
medline: 5 3 2020
entrez: 11 8 2018
Statut: ppublish

Résumé

Individuals with 22q11.2 Deletion Syndrome (22q11.2DS) are at substantially heightened risk for psychosis. Thus, prevention and early intervention strategies that target the antecedents of psychosis in this high-risk group are a clinical priority. Attention Deficit Hyperactivity Disorder (ADHD) is one the most prevalent psychiatric disorders in children with 22q11.2DS, particularly the inattentive subtype. The aim of this study was to test the hypothesis that ADHD inattention symptoms predict later psychotic symptoms and/or psychotic disorder in those with 22q11.2DS. 250 children and adolescents with 22q11.2DS without psychotic symptoms at baseline took part in a longitudinal study. Assessments were performed using well-validated structured diagnostic instruments at two time points (T1 (mean age = 11.2, SD = 3.1) and T2 (mean age = 14.3, SD = 3.6)). Inattention symptoms at T1 were associated with development of psychotic symptoms at T2 (OR:1.2, p = 0.01) but weak associations were found with development of psychotic disorder (OR:1.2, p = 0.15). ADHD diagnosis at T1 was strongly associated with development of psychotic symptoms at T2 (OR:4.5, p < 0.001) and psychotic disorder (OR:5.9, p = 0.02). Our findings that inattention symptoms and the diagnosis of ADHD are associated with subsequent psychotic outcomes in 22q11.2DS have important clinical implications. Future studies examining the effects of stimulant and other ADHD treatments on individuals with 22q11.2DS are warranted.

Identifiants

DOI: 10.1016/j.schres.2018.07.044 PMID: 30093352 PMC: PMC6406019
pubmed: 30093352
pii: S0920-9964(18)30490-0
doi: 10.1016/j.schres.2018.07.044
pmc: PMC6406019
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

320-325

Subventions

Organisme : NIMH NIH HHS
ID : U01 MH101720
Pays : United States
Organisme : MRF
ID : MRF_MRF-154-0001-RG-SKUSE
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L011166/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : R01 MH085953
Pays : United States
Organisme : NIBIB NIH HHS
ID : U54 EB020403
Pays : United States
Organisme : Medical Research Council
ID : MR/P005748/1
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : U01 MH101719
Pays : United States
Organisme : Wellcome Trust
ID : 110222/Z/15/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Am J Psychiatry. 2013 May;170(5):550-7
pubmed: 23632836
Nat Rev Dis Primers. 2015 Nov 19;1:15071
pubmed: 27189754
J Am Acad Child Adolesc Psychiatry. 1993 May;32(3):643-50
pubmed: 8496128
Can J Psychiatry. 2015 Mar;60(3 Suppl 2):S48-52
pubmed: 25886680
Eur Psychiatry. 2014 May;29(4):259-63
pubmed: 24016863
Stat Med. 2002 Aug 30;21(16):2409-19
pubmed: 12210625
Nat Rev Neurosci. 2009 Jan;10(1):48-58
pubmed: 19050712
J Neurodev Disord. 2015;7(1):18
pubmed: 26137170
Hum Mol Genet. 2013 Nov 15;22(22):4485-501
pubmed: 23813976
Am J Psychiatry. 2014 Jun;171(6):627-39
pubmed: 24577245
Br J Psychiatry. 2014 Jan;204(1):46-54
pubmed: 24115343
Am J Psychiatry. 2000 Sep;157(9):1416-22
pubmed: 10964857
Schizophr Bull. 2009 May;35(3):549-62
pubmed: 19325164
Schizophr Res. 2007 May;92(1-3):116-25
pubmed: 17344028
Psychol Med. 1995 Jul;25(4):739-53
pubmed: 7480451
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
pubmed: 9204677
J Psychiatr Res. 2017 Sep;92:124-131
pubmed: 28433949
J Am Acad Child Adolesc Psychiatry. 2000 Jan;39(1):59-66
pubmed: 10638068
Nat Genet. 2019 Jan;51(1):63-75
pubmed: 30478444
World J Psychiatry. 2015 Mar 22;5(1):47-55
pubmed: 25815254
Schizophr Bull. 2016 Jul;42(4):942-51
pubmed: 26884546
Mol Psychiatry. 2017 Dec;22(12):1664-1672
pubmed: 28761081
Br J Psychiatry. 2017 Oct;211(4):223-230
pubmed: 28882829
Am J Med Genet B Neuropsychiatr Genet. 2015 Dec;168(8):730-8
pubmed: 26400629
J Am Acad Child Adolesc Psychiatry. 1995 Oct;34(10):1273-83
pubmed: 7592264
Am J Med Genet A. 2005 Nov 1;138(4):307-13
pubmed: 16208694
Dev Disabil Res Rev. 2008;14(1):3-10
pubmed: 18636631
J Neurodev Disord. 2012 Jul 06;4(1):19
pubmed: 22958744
J Child Adolesc Psychopharmacol. 2011 Dec;21(6):589-95
pubmed: 22149470
Schizophr Res. 2014 Mar;153(1-3):231-6
pubmed: 24534796
Br J Psychiatry. 2014 Feb;204(2):108-14
pubmed: 24311552
Neurosci Biobehav Rev. 2006;30(5):651-65
pubmed: 16466794
Schizophr Bull. 2018 Jun 6;44(4):824-833
pubmed: 29040797
Br J Psychiatry. 2013 Aug;203(2):107-11
pubmed: 23703318
Soc Psychiatry Psychiatr Epidemiol. 2011 Jan;46(1):17-27
pubmed: 19907910
Schizophr Res. 2017 Oct;188:59-62
pubmed: 28119035

Auteurs

Maria Niarchou (M)

Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom; Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia. Electronic address: niarchoum@cardiff.ac.uk.

Samuel J R A Chawner (SJRA)

Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom.

Ania Fiksinski (A)

Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands; Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; The Dalglish Family 22q Clinic for 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

Jacob A S Vorstman (JAS)

Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; The Dalglish Family 22q Clinic for 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; The Hospital for Sick Children, Toronto, Canada.

Johanna Maeder (J)

Department of Psychiatry, University of Geneva, Geneva, Switzerland.

Maude Schneider (M)

Department of Psychiatry, University of Geneva, Geneva, Switzerland.

Stephan Eliez (S)

Department of Psychiatry, University of Geneva, Geneva, Switzerland.

Marco Armando (M)

Department of Psychiatry, University of Geneva, Geneva, Switzerland.

Maria Pontillo (M)

Paediatric Hospital Bambino Gesu, Rome, Italy.

Stefano Vicari (S)

Paediatric Hospital Bambino Gesu, Rome, Italy.

Donna M McDonald-McGinn (DM)

Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Beverly S Emanuel (BS)

Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Elaine H Zackai (EH)

Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Carrie E Bearden (CE)

Semel Institute for Neuroscience and Human Behavior and Department of Psychology, UCLA, CA, USA.

Vandana Shashi (V)

Department of Pediatrics, Duke University School of Medicine, Durham, USA.

Stephen R Hooper (SR)

Department of Allied Health Sciences, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Michael J Owen (MJ)

Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom.

Raquel E Gur (RE)

Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Psychiatry, Neuropsychiatry Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Child and Adolescent Psychiatry, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Naomi R Wray (NR)

Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.

Marianne B M van den Bree (MBM)

Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom.

Anita Thapar (A)

Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Attention deficit hyperactivity disorder...
questionsmedicales.fr › Troubles mentaux › Troubles du développement neurologique › Troubles déficitaires de l'attention et du comportement perturbateur › Trouble déficitaire de l'attention avec hyperactivité › Attention deficit hyperactivity disorder...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Attention deficit hyperactivity disorder...
questionsmedicales.fr › Maladies endocriniennes › Maladies de la parathyroïde › Hypoparathyroïdie › Syndrome de délétion 22q11 › Syndrome de DiGeorge › Attention deficit hyperactivity disorder...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Attention deficit hyperactivity disorder...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Attention deficit hyperactivity disorder...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études longitudinales › Attention deficit hyperactivity disorder...
questionsmedicales.fr › Troubles mentaux › Schizophrénie et troubles avec traits psychotiques › Troubles psychotiques › Attention deficit hyperactivity disorder...